Types of PEG-Free Lipid Nanoparticle Coatings: Synthesis, Characterization, and In Vivo Delivery

Types of PEG-Free Lipid Nanoparticle Coatings: Synthesis, Characterization, and In Vivo Delivery

What Are PEG-Free Lipid Nanoparticle Coatings?

PEG-free lipid nanoparticle (LNP) coatings are non-polyethylene glycol (non-PEG) surface modifications designed to provide colloidal stability, regulate interactions with biological components, and maintain efficient cellular delivery. Conventional LNPs commonly contain four major lipid components: an ionizable lipid, a helper phospholipid, cholesterol, and a PEG-lipid. The PEG-lipid consists of a hydrophilic PEG chain attached to a hydrophobic lipid anchor, allowing the polymer chain to extend from the nanoparticle surface and form a hydrated steric barrier. This surface layer can reduce particle aggregation and nonspecific protein adsorption, but it may also restrict interactions between LNPs and cell membranes.

Interest in PEG-free coatings has increased because PEGylated surfaces can introduce formulation-specific limitations, including interactions with pre-existing or treatment-induced anti-PEG antibodies, altered nanoparticle clearance, and reduced cellular uptake or endosomal escape under certain conditions. These effects are not universal and depend on the complete lipid composition, polymer architecture, administration route, and biological environment. Nevertheless, replacing PEG-lipids with alternative hydrophilic polymers or biomimetic materials provides an opportunity to redesign the LNP-biointerface rather than simply modifying the PEG chain.

Structurally, PEG-free coatings generally retain the lipid-based nanoparticle core while replacing the external PEG layer with a different hydrophilic surface component. The coating can be introduced through a polymer-lipid conjugate incorporated during LNP formation, post-assembly covalent attachment to reactive surface lipids, or noncovalent adsorption of a polymer onto the nanoparticle surface. The selected architecture determines polymer retention, surface density, hydration, charge distribution, and compatibility with the encapsulated payload.

Four representative categories are particularly relevant to current PEG-free LNP development. Zwitterionic polymers provide strongly hydrated surfaces through paired positive and negative charges. Polysarcosine offers a neutral, hydrophilic polypeptoid coating. Poly(2-oxazoline) provides a tunable synthetic polymer architecture with adjustable chain length and terminal functionality. Polysaccharides offer hydrated, biologically derived surface structures that can also influence interactions with specific cellular environments.

Table 1. Major Types of PEG-Free Lipid Nanoparticle Coatings and Their Design Characteristics.

Coating TypeRepresentative MaterialsSurface CharacteristicsPrimary Development FocusResearch Evidence
Zwitterionic Polymer CoatingsPoly(carboxybetaine) (PCB), pH-responsive polycarboxybetaine, and phosphorylcholine-based polymersHydrated surfaces containing both positive and negative ionic groupsProtein adsorption, charge responsiveness, cellular uptake, and membrane interactionDirect LNP studies involving siRNA and mRNA delivery
Polysarcosine CoatingsPolysarcosine-lipid conjugates, including DMG-pSar and other lipid-anchored pSar structuresNeutral, hydrophilic polymer chains with adjustable molecular weightPEG-lipid replacement, surface shielding, lipid-anchor selection, and delivery efficiencyDirect mRNA-LNP formulation and in vivo research
Poly(2-oxazoline) CoatingsPoly(2-ethyl-2-oxazoline) (PEtOx) and poly(2-methyl-2-oxazoline) (PMeOx)Nonionic, hydrophilic polymer chains with tunable repeat unitsPolymer chain length, terminal functionalization, surface density, and transfectionDirect PEtOx-lipid LNP formulation and in vitro studies
Polysaccharide CoatingsHeparosan, hyaluronic acid, and selected dextran derivativesHydrophilic carbohydrate chains with adjustable charge and molecular weightSurface hydration, biological interactions, polymer retention, and tissue distributionDirect heparosan-coated mRNA-LNP research with in vivo evaluation

The selection of a PEG-free coating should consider more than its ability to prevent particle aggregation. Polymer molecular weight, lipid-anchor structure, surface coverage, linker stability, and the original LNP composition collectively determine whether the modified particle can retain its encapsulated payload and achieve productive intracellular delivery. For example, a highly hydrated coating may improve colloidal stability but reduce membrane interactions if its surface density is excessive. Conversely, insufficient polymer coverage may leave hydrophobic regions exposed and increase nonspecific interactions with serum proteins.

The choice should therefore be guided by the intended payload, target tissue, administration route, and required biological performance. BOC Sciences provides zwitterionic-functionalized lipid nanoparticle development and broader PEG-free LNP research support, including polymer-lipid building block selection, custom synthesis, surface modification, formulation development, and physicochemical and biological evaluation.

Zwitterionic Polymer-Coated Lipid Nanoparticles

What Are Zwitterionic Polymer-Coated LNPs and When Are They Needed?

Zwitterionic polymer-coated LNPs are nanoparticles whose external surface contains polymers with both positively and negatively charged functional groups. These groups can generate a strongly hydrated interfacial layer through electrostatic interactions with surrounding water molecules. Unlike conventional neutral polymers, zwitterionic materials maintain paired ionic functionalities within their molecular structure, which can help reduce nonspecific interactions with proteins and other biological components.

Poly(carboxybetaine) (PCB) and phosphorylcholine-containing polymers are representative zwitterionic materials. PCB contains quaternary ammonium and carboxylate groups, while phosphorylcholine-based polymers reproduce important hydration characteristics of phospholipid headgroups. A related research direction involves pH-responsive polycarboxybetaine structures, such as poly(glutamate)-based polymers modified with diethylenetriamine-derived carboxybetaine groups. These materials can change their charge characteristics under different pH conditions, providing an additional mechanism for regulating cellular interactions.

Research has demonstrated that the molecular weight and surface density of zwitterionic polymers can substantially influence LNP behavior. In one representative siRNA-LNP study, pH-responsive polycarboxybetaine coatings with different polymerization degrees were compared. Shorter polymer chains showed more favorable pH-dependent membrane interactions and gene-silencing activity, whereas excessive polymer length could restrict lipid-membrane interactions. Other research has investigated PCB-containing lipid structures as PEG-lipid alternatives for mRNA delivery, including cellular and mouse studies.

Zwitterionic coatings are particularly worth investigating when a formulation requires reduced nonspecific protein adsorption, improved colloidal stability, or a more controllable surface-charge environment. They may also be useful when conventional steric shielding interferes with cellular uptake. However, zwitterionic modification does not automatically improve delivery. The final surface must balance hydration and antifouling behavior with sufficient membrane interaction and intracellular payload release.

Synthesis Methods of Zwitterionic Polymer-Coated LNPs

The preparation of zwitterionic LNPs generally involves two connected operations: synthesis of the zwitterionic polymer or polymer-lipid conjugate, followed by incorporation into the nanoparticle surface. The most suitable route depends on the polymer backbone, available terminal functional groups, and whether the coating is intended to be integrated during particle formation or attached after the LNP core has been prepared.

Step 1: Zwitterionic polymer synthesis. PCB and related polycarboxybetaine materials can be prepared through polymerization of suitable betaine-containing monomers or through post-polymerization modification of a functional polymer backbone. Polymerization conditions should be selected to control molecular weight, dispersity, and functional-group availability. For pH-responsive structures, the balance between protonatable amine groups and carboxylate groups requires particular attention because it determines the polymer's charge response under different environmental conditions.

Step 2: Polymer-lipid conjugation. A hydrophobic lipid anchor can be connected to the zwitterionic polymer through terminal-group coupling. Depending on the selected structure, suitable reactions may include amide formation, click chemistry, or other compatible conjugation strategies. For example, a polycarboxybetaine polymer can be functionalized with an azide group and connected to a lipid anchor bearing a complementary reactive group. The conjugate should be purified and chemically characterized before it is introduced into the LNP formulation.

Step 3: LNP preparation and coating incorporation. A representative strategy uses an ionizable lipid, helper phospholipid, and cholesterol to prepare the payload-containing nanoparticle core. The zwitterionic polymer-lipid conjugate can be included in the organic lipid phase before microfluidic mixing. This allows the hydrophobic anchor to associate with the lipid assembly while the hydrophilic polymer chain is presented at the particle-water interface. Alternatively, preformed LNPs containing suitable reactive surface groups can undergo post-assembly conjugation.

Step 4: Surface-density optimization. The polymer-to-lipid ratio, polymer molecular weight, and lipid-anchor structure should be screened systematically. Excessive polymer incorporation can create a thick hydrated layer that limits membrane contact, whereas insufficient incorporation may fail to establish the desired surface characteristics. A formulation series with different coating fractions is more informative than relying on a single nominal polymer feed ratio.

Purification and Characterization of Zwitterionic Polymer-Coated LNPs

Purification should remove free polymer, unreacted lipid conjugates, coupling reagents, and residual organic solvent without disrupting the polymer layer or damaging the encapsulated payload. Dialysis, ultrafiltration, tangential flow filtration, and size-exclusion chromatography can be considered according to the molecular weight of the free polymer and the hydrodynamic size of the LNP population. The separation method should be selected based on actual recovery and polymer-removal performance.

Polymer identity and conjugation: Proton nuclear magnetic resonance (1H NMR), Fourier-transform infrared spectroscopy (FTIR), and size-exclusion chromatography can be used to characterize the polymer and confirm changes associated with lipid conjugation. Where appropriate, mass spectrometry or other molecular analysis can provide additional information about conjugate composition and molecular-weight distribution.

Particle size and surface charge: Dynamic light scattering (DLS) provides hydrodynamic diameter and polydispersity index (PDI), while zeta-potential analysis evaluates changes in the electrokinetic surface potential. Because zwitterionic groups contain opposing charges, a near-neutral zeta potential does not independently prove successful coating. Polymer-associated measurements and comparison with unmodified particles are also required.

Surface hydration and protein interactions: Protein adsorption studies can help determine whether the coating reduces nonspecific association with biological proteins. Surface polymer content should be quantified using an appropriate polymer-specific or labeled-polymer method. Cryogenic transmission electron microscopy (cryo-TEM) can provide complementary information about particle morphology, although a highly hydrated polymer layer may not be clearly visible.

Payload integrity and functional properties: Encapsulation efficiency, RNA integrity, and colloidal stability should be assessed after coating and purification. For siRNA formulations, gene-silencing activity provides a functional measure of delivery. For mRNA formulations, reporter expression or production of the encoded protein can indicate whether surface modification preserves intracellular delivery. These measurements should be integrated with lipid nanoparticle characterization, including particle size analysis and zeta-potential analysis.

Delivery Strategies of Zwitterionic Polymer-Coated LNPs

The administration route should be selected according to the target tissue, payload properties, and biological behavior of the final formulation. Zwitterionic surface hydration may reduce nonspecific protein adsorption, but the resulting distribution is still influenced by particle size, ionizable lipid composition, surface density, and interactions with biological membranes. Therefore, a coating that improves stability in a buffer or serum-containing medium should not automatically be assumed to improve systemic delivery.

Intravenous administration: This route may be evaluated when the formulation is intended to reach tissues through systemic circulation. The zwitterionic layer should maintain sufficient stability after dilution and exposure to serum proteins. Particle size, surface charge, protein adsorption, and organ accumulation should be monitored to determine whether the coating changes circulation and tissue distribution.

Local administration: Local injection may be appropriate when the target tissue is accessible and high local particle exposure is preferred. This route can reduce dependence on systemic distribution, but the coating must remain sufficiently stable in the local tissue environment. Tissue diffusion, extracellular matrix interactions, and local cellular uptake should be evaluated.

pH-responsive delivery: Certain polycarboxybetaine architectures can be designed to change their charge characteristics under mildly acidic conditions. Such materials may support stronger cellular association or membrane interactions in selected acidic environments. Their usefulness depends on whether the polymer responds within the relevant pH range without destabilizing the LNP during preparation, storage, or circulation.

Payload-dependent optimization: siRNA and mRNA formulations require cytosolic delivery after cellular uptake. The coating should therefore provide sufficient surface hydration without excessively restricting membrane interactions or endosomal escape. For different nucleic acid payloads, the ionizable lipid, helper phospholipid, and polymer-lipid ratio should be optimized together rather than independently.

Delivery Verification of Zwitterionic Polymer-Coated LNPs

In vivo verification should distinguish nanoparticle distribution from cellular internalization and functional payload delivery. A zwitterionic coating may alter protein adsorption and tissue exposure without necessarily increasing the amount of payload reaching the cytosol. A combination of imaging, tissue analysis, cellular measurements, and payload-specific functional readouts is therefore needed.

Whole-body and organ distribution: A traceable lipid component can be incorporated into the LNP to monitor particle-associated signals after administration. Whole-body imaging provides an overview of distribution over time, while organ collection and quantitative analysis help determine accumulation in the target tissue and major clearance organs. If possible, the polymer coating and encapsulated payload should be tracked separately to identify coating detachment or particle disassembly.

Cell-specific uptake: Flow cytometry and confocal microscopy can determine which cell populations associate with or internalize the nanoparticles. These measurements can be combined with receptor-expression analysis or other relevant cellular markers. The results should distinguish surface-associated particles from intracellular material and avoid interpreting total tissue fluorescence as proof of functional delivery.

Intracellular trafficking and endosomal escape: Colocalization analysis with endosomal and lysosomal markers can help evaluate intracellular transport. Cytosolic delivery should be supported by functional payload readouts rather than inferred solely from cellular uptake. Nanoparticle intracellular localization detection can provide complementary information about intracellular distribution.

Functional delivery and repeat administration: Reporter expression, target-protein production, or gene-silencing measurements can establish whether the payload remains biologically active after administration. For repeated-dose studies, compare the expression profile, tissue distribution, and relevant immune-response indicators across dosing cycles. Such measurements are important because replacing PEG does not guarantee the absence of polymer-specific biological responses or accelerated particle clearance.

Table 2. Development and Evaluation Workflow for Zwitterionic Polymer-Coated LNPs.

Development StageRepresentative Methods and Readouts
Synthesis MethodsControlled polymer synthesis, terminal-group functionalization, polymer-lipid conjugation, and microfluidic LNP preparation or post-assembly surface coupling. Evaluate molecular weight, conjugation efficiency, polymer-to-lipid ratio, and surface incorporation.
In Vitro EvaluationDLS, PDI, zeta potential, cryo-TEM, polymer quantification, protein adsorption analysis, cellular uptake, membrane interaction, intracellular localization, and reporter expression or gene-silencing assays.
Delivery RouteIntravenous or local administration according to target tissue accessibility, surface stability, payload requirements, and the intended biological distribution.
In Vivo VerificationWhole-body imaging, organ distribution, tissue flow cytometry, microscopy, intracellular trafficking, reporter expression, and target-gene or protein analysis. Include repeat-administration evaluation when relevant.
Developing Zwitterionic Polymer-Coated LNPs?

BOC Sciences provides support for zwitterionic polymer selection, polymer-lipid conjugation, custom material synthesis, LNP surface modification, and physicochemical and biological evaluation to help optimize PEG-free nanoparticle formulations.

Polysarcosine-Coated Lipid Nanoparticles

What Are Polysarcosine-Coated LNPs and When Are They Needed?

Polysarcosine-coated LNPs use polysarcosine (pSar), a hydrophilic polypeptoid composed of repeating N-methylglycine units, as a non-PEG surface polymer. Unlike conventional polypeptides, pSar has a methylated backbone nitrogen and does not contain the same repeating side-chain structure as naturally occurring proteins. Its neutral character, water solubility, and ability to form hydrated polymer layers make it an interesting alternative to PEG-lipids.

In a typical pSar-LNP architecture, the polymer is covalently connected to a hydrophobic lipid anchor. The anchor associates with the lipid nanoparticle, while the pSar chain extends into the aqueous environment. Representative structures include dimyristoyl glycerol-pSar (DMG-pSar) and other pSar conjugates with different lipid-chain architectures. The polymer chain length and anchor structure determine how the coating is presented at the nanoparticle surface.

Research has directly investigated pSar-lipid conjugates as PEG-lipid replacements in mRNA-loaded LNPs. In one study, pSar chains with different lengths and lipid anchors were incorporated into LNP formulations. The results showed that pSar could maintain or improve mRNA delivery depending on the underlying ionizable lipid and the specific pSar-lipid structure. Mouse studies also demonstrated measurable mRNA expression following intramuscular administration of selected pSar-LNP formulations.

Polysarcosine coatings are particularly relevant when researchers want to replace PEG-lipids while maintaining a hydrophilic surface layer and avoiding excessive interference with intracellular delivery. They may also be considered when polymer molecular weight and lipid-anchor structure need to be independently adjusted. However, the performance of one pSar-lipid structure cannot be generalized to all pSar-LNPs because polymer length, anchor hydrophobicity, lipid composition, and surface density can produce substantially different particle properties.

Synthesis Methods of Polysarcosine-Coated LNPs

The development of pSar-coated LNPs involves synthesis of the polymer, introduction of a lipid-compatible functional group, preparation of the pSar-lipid conjugate, and incorporation of the conjugate into the nanoparticle. A controlled polymerization process is important because the molecular weight and end-group chemistry influence both conjugation efficiency and the final surface architecture.

Step 1: Polysarcosine synthesis. A common approach uses the ring-opening polymerization of sarcosine N-carboxyanhydride (Sar-NCA), initiated by an appropriate amine-containing initiator. The monomer-to-initiator ratio provides a means of controlling the target degree of polymerization. Functional initiators can introduce terminal groups such as azide or other reactive functionalities for subsequent lipid conjugation. Alternative monomer and polymerization routes may also be considered according to the desired polymer structure and synthesis requirements.

Step 2: Lipid-anchor conjugation. The terminal functional group of pSar is connected to a hydrophobic lipid component. Suitable conjugation strategies depend on the selected end group and lipid structure and may include click reactions or other chemoselective coupling methods. The resulting pSar-lipid should be purified to remove unreacted polymer, free lipid, and low-molecular-weight reaction byproducts. NMR and size-exclusion chromatography can help verify conjugate formation and polymer characteristics.

Step 3: LNP formulation. The pSar-lipid conjugate can be introduced into the lipid mixture before nanoparticle formation. The organic phase generally contains the ionizable lipid, helper phospholipid, cholesterol, and pSar-lipid, while the aqueous phase contains the payload in a suitable buffer. Rapid mixing or lipid nanoparticle synthesis using a microfluidic approach can facilitate simultaneous particle formation and pSar-lipid incorporation.

Step 4: Polymer-length and anchor screening. Different pSar chain lengths and lipid anchors should be compared while maintaining a controlled base formulation. For example, research comparing pSar chains with different degrees of polymerization found that longer chains could reduce mRNA delivery efficiency, consistent with excessive steric shielding. Lipid-anchor structure also influenced particle size and functional delivery, demonstrating that polymer chemistry cannot be optimized independently of the hydrophobic component.

Post-insertion of pSar-lipid conjugates into preformed LNPs may also be investigated when the original particle core has already been optimized. However, insertion efficiency, lipid exchange, and polymer retention should be measured directly. The pre-insertion and post-insertion approaches should be compared according to formulation stability and the ability to preserve payload encapsulation.

Purification and Characterization of Polysarcosine-Coated LNPs

Purification of pSar-LNPs should remove free pSar, unincorporated pSar-lipid conjugates, and residual processing components while preserving the surface-associated polymer. Dialysis and ultrafiltration can be used for buffer exchange and removal of smaller soluble components. Size-exclusion chromatography or other separation approaches may be useful when free conjugates and nanoparticle populations have sufficiently different hydrodynamic properties.

Polymer and conjugate characterization: NMR spectroscopy can confirm the chemical structure of pSar and identify signals associated with the lipid anchor. Size-exclusion chromatography can evaluate molecular-weight distribution and polymer dispersity. The conjugation ratio and residual free polymer should be assessed before the material is used for LNP preparation.

Particle size and morphology: DLS provides hydrodynamic diameter and PDI, while cryo-TEM can examine nanoparticle morphology. A change in particle size after pSar-lipid incorporation may reflect the formation of a hydrated polymer layer, but excessive size increases or broad particle distributions may indicate aggregation or incompatible lipid packing.

Surface incorporation and colloidal stability: The amount of particle-associated pSar should be measured using an appropriate polymer-specific quantification method or a validated labeled-polymer approach. Zeta potential can provide supplementary information about changes in the particle interface, although neutral pSar chains may not generate a large charge shift. Particle size and PDI should also be monitored after dilution, storage, and exposure to relevant biological media. A broader lipid nanoparticle stability evaluation can help determine whether the pSar layer remains associated with the particle.

Payload encapsulation and integrity: Encapsulation efficiency should be measured after formulation and purification. RNA integrity can be evaluated using electrophoretic or chromatographic methods, while payload leakage should be assessed under relevant storage and biological exposure conditions. Nanoparticle drug loading analysis can provide complementary information about the amount of encapsulated material and changes following surface modification.

Functional delivery: For mRNA-LNPs, reporter expression or encoded-protein production provides a direct indication of functional delivery. For siRNA-LNPs, target transcript and protein reduction should be measured. These functional readouts are essential because a pSar coating may maintain high encapsulation efficiency without necessarily supporting efficient cytosolic payload release.

Delivery Strategies of Polysarcosine-Coated LNPs

The delivery route for pSar-LNPs should be selected according to the target tissue, payload, and intended distribution profile. The hydrated pSar layer may reduce nonspecific surface interactions, but the degree of shielding must remain compatible with cellular uptake and intracellular release. Its effects depend on the polymer chain length, lipid-anchor structure, and composition of the underlying nanoparticle.

Intravenous delivery: Systemic administration can be considered when the target tissue is accessible through circulation. The pSar layer should be evaluated for its ability to maintain particle integrity after serum exposure and dilution. The lipid anchor must also provide sufficient retention within the LNP to prevent premature loss of the surface polymer. Organ distribution, protein adsorption, and target-cell uptake should be compared with the unmodified formulation.

Intramuscular delivery: Intramuscular administration has been directly investigated in mouse studies using selected pSar-LNP formulations containing mRNA. Reporter expression and encoded-protein measurements demonstrated that pSar-lipid replacement can maintain or improve functional delivery in certain lipid compositions. These findings support further investigation of pSar-LNPs for local administration, but the results should not be generalized to all polymer lengths or ionizable lipid systems.

Local administration: Other local routes may be considered when the target tissue is accessible and systemic distribution is not essential. The formulation should be evaluated for local retention, tissue diffusion, and cellular uptake. Polymer hydration can influence particle movement through biological environments, making surface density an important parameter for localized delivery.

Balancing shielding and endosomal escape: A pSar coating that is too dense or too long may reduce the interaction between the underlying lipid components and endosomal membranes. Therefore, pSar chain length and molar fraction should be optimized together with the ionizable lipid and helper phospholipid. The goal is to preserve extracellular stability without compromising intracellular release.

Delivery Verification of Polysarcosine-Coated LNPs

In vivo delivery verification should establish whether pSar modification changes nanoparticle distribution, cellular uptake, and payload expression. The lipid component and encapsulated payload should be distinguished whenever possible because a nanoparticle-associated signal does not necessarily indicate that the cargo has reached its functional destination.

Whole-body distribution: A traceable lipid component can be used to follow nanoparticle-associated signals after administration. Imaging at multiple time points can reveal the distribution pattern and signal persistence. Organ collection and quantitative analysis should then be used to determine whether the formulation accumulates in the intended tissue or is predominantly associated with clearance organs.

Tissue-level delivery: The target tissue should be analyzed for both nanoparticle-associated signals and payload activity. For mRNA formulations, reporter expression and encoded-protein levels can indicate successful delivery. For siRNA, tissue-specific target-gene reduction can provide a functional readout. If the formulation is designed for local administration, the distribution between the injection site and surrounding tissues should also be evaluated.

Cellular uptake and intracellular localization: Tissue dissociation followed by flow cytometry can identify particle-associated signals in relevant cell populations. Microscopy can provide spatial information about particle localization. Endosomal and lysosomal colocalization measurements can further help determine whether the payload remains trapped in intracellular compartments.

Repeat-administration evaluation: When repeated administration is relevant, compare particle distribution and payload expression after the initial and subsequent doses. Monitor changes in relevant immune-response indicators and assess whether the polymer coating remains associated with the nanoparticle. The absence of PEG does not exclude the possibility of biological responses to pSar or other formulation components.

Nanoparticle in vivo imaging can support the visualization of particle-associated signals, while in vivo distribution analysis can provide quantitative organ-level information. These measurements should be combined with payload-specific expression or gene-silencing data.

Table 3. Development and Evaluation Workflow for Polysarcosine-Coated LNPs.

Development StageRepresentative Methods and Readouts
Synthesis MethodsSar-NCA polymerization, pSar end-group functionalization, lipid-anchor conjugation, and microfluidic LNP formulation. Evaluate polymer molecular weight, degree of polymerization, conjugate purity, lipid-anchor structure, and surface incorporation.
In Vitro EvaluationDLS, PDI, zeta potential, cryo-TEM, polymer quantification, encapsulation efficiency, RNA integrity, cellular uptake, endosomal escape, reporter expression, and gene-silencing analysis.
Delivery RouteIntravenous, intramuscular, or other local administration according to target tissue and payload requirements. Evaluate serum stability, local retention, tissue exposure, and functional delivery.
In Vivo VerificationWhole-body imaging, organ distribution, tissue-level reporter expression, encoded-protein quantification, cell-specific uptake, and repeat-administration assessment when relevant.
Need Custom Polysarcosine-Lipid Building Blocks for Your LNPs?

BOC Sciences supports pSar material selection, polymer synthesis, lipid-anchor conjugation, PEG-free LNP formulation, and delivery evaluation to help develop customized polysarcosine-coated nanoparticles.

Poly(2-oxazoline)-Coated Lipid Nanoparticles

What Are Poly(2-oxazoline)-Coated LNPs and When Are They Needed?

Poly(2-oxazoline)-coated LNPs use poly(2-oxazoline) (POx) polymers as nonionic hydrophilic alternatives to PEG. POx is a family of synthetic polymers with a tertiary amide-containing backbone and side-chain structures that can be modified by selecting different 2-substituted-2-oxazoline monomers. Poly(2-ethyl-2-oxazoline) (PEtOx) and poly(2-methyl-2-oxazoline) (PMeOx) are representative materials investigated for their high water solubility, adjustable molecular weight, and potential to reduce nonspecific interactions.

In a typical POx-LNP architecture, a hydrophilic POx chain is connected to a hydrophobic lipid anchor. The lipid component associates with the nanoparticle surface, while the polymer extends into the surrounding aqueous phase. This structure resembles the amphiphilic organization of conventional PEG-lipids but uses a chemically distinct polymer backbone. The polymerization degree, side-chain structure, terminal functionality, and lipid-anchor composition determine the resulting surface properties.

Research on PEtOx-lipid conjugates has demonstrated their use in mRNA-loaded LNP formulations. Studies comparing different PEtOx chain lengths have evaluated particle size, morphology, encapsulation, and cellular transfection. These results indicate that POx molecular weight is an important design variable and that selected PEtOx-lipid structures can support functional mRNA delivery in vitro. However, LNP-specific in vivo evidence remains less extensive than the published research on polysarcosine and selected polysaccharide coatings.

POx coatings are worth investigating when a project requires a synthetic, nonionic, hydrophilic polymer with controllable chain length and terminal chemistry. They are also useful when the polymer backbone and lipid anchor need to be independently modified to explore structure-property relationships. Their suitability should be established through direct LNP formulation and biological evaluation rather than inferred solely from the performance of POx in other nanoparticle systems.

Synthesis Methods of Poly(2-oxazoline)-Coated LNPs

POx-LNP preparation generally begins with controlled polymer synthesis, followed by end-group functionalization and attachment of a hydrophobic lipid anchor. Because the polymer chain length influences its hydrodynamic behavior and surface shielding, the synthesis route should provide reproducible molecular-weight distribution and defined terminal functionality.

Step 1: POx polymer synthesis. Poly(2-oxazoline) can be prepared through living cationic ring-opening polymerization (CROP) of a selected 2-substituted-2-oxazoline monomer. For PEtOx, 2-ethyl-2-oxazoline is used as the monomer. The monomer-to-initiator ratio provides a means of controlling the degree of polymerization, while the initiator and termination conditions determine the polymer end groups. This approach allows the synthesis of POx chains with selected molecular weights and functionalization potential.

Step 2: Terminal functionalization. The polymer end group can be modified to introduce a carboxyl, amino, azide, or other reactive functionality suitable for lipid conjugation. The selected modification should preserve the polymer backbone and avoid unnecessary changes to its hydrophilic properties. NMR spectroscopy and size-exclusion chromatography can be used to evaluate polymer structure and molecular-weight distribution.

Step 3: POx-lipid conjugation. A hydrophobic lipid anchor can be connected to the functionalized polymer through amide coupling, click chemistry, or other suitable conjugation reactions. Research has demonstrated the preparation of PEtOx-lipid structures using controlled polymerization followed by post-polymerization functionalization and lipid coupling. The resulting conjugate should be purified to remove free polymer and lipid components before formulation.

Step 4: LNP formulation. The purified POx-lipid conjugate is incorporated into the lipid mixture together with the ionizable lipid, helper phospholipid, and cholesterol. The lipid phase is then mixed with the aqueous payload phase using an appropriate rapid-mixing process. The LNP formulation process should be optimized to obtain suitable particle size, PDI, encapsulation efficiency, and colloidal stability.

Step 5: Polymer-length screening. Different POx polymerization degrees should be compared rather than assuming that the molecular weight corresponding to a PEG chain will produce an equivalent hydrodynamic layer. PEG and POx differ in backbone chemistry, hydration, and chain conformation. The final design should therefore be based on measured particle properties and biological performance.

Purification and Characterization of Poly(2-oxazoline)-Coated LNPs

Purification should remove unreacted polymer, free lipid anchors, residual monomers, and small-molecule reaction components. Precipitation, dialysis, and ultrafiltration can be selected according to the solubility and molecular-weight characteristics of the POx-lipid conjugate. Following LNP preparation, dialysis or tangential flow filtration can remove organic solvent and exchange the formulation buffer. The recovery of the nanoparticle population and retention of the surface polymer should be monitored during purification.

Polymer molecular characterization: NMR spectroscopy can confirm the POx backbone and terminal functional groups. Size-exclusion chromatography can assess molecular-weight distribution and dispersity. Additional analysis of the polymer-lipid conjugate should confirm that the hydrophobic anchor has been successfully introduced.

Particle size and morphology: DLS can determine hydrodynamic diameter and PDI, while cryo-TEM can provide information about particle morphology and structural uniformity. Nanoparticle tracking or other particle-sizing approaches may provide complementary information about particle concentration and distribution.

Surface modification and stability: The amount of particle-associated POx should be evaluated using an appropriate analytical method. Because POx is generally nonionic, zeta-potential changes may be relatively small and should not be used as the sole indicator of surface incorporation. Protein adsorption, serum stability, and particle aggregation should be evaluated under relevant conditions.

Payload integrity and functional performance: Encapsulation efficiency and RNA integrity should be determined after formulation and purification. Cellular uptake, intracellular localization, and reporter expression provide complementary information about the relationship between particle structure and functional delivery. The results should be compared with an unmodified or appropriately selected reference formulation to determine whether the POx coating provides a meaningful improvement.

Delivery Strategies of Poly(2-oxazoline)-Coated LNPs

POx-LNP delivery strategies should be developed according to the target tissue, payload, and measured surface properties. The nonionic hydrated layer may reduce nonspecific protein adsorption and improve colloidal stability, but excessive shielding can also restrict interactions with cellular membranes. Consequently, the polymer molecular weight and surface density should be optimized in conjunction with the lipid composition.

Systemic delivery: Intravenous administration can be evaluated when circulation-mediated tissue delivery is required. The formulation should be assessed for stability after dilution, protein adsorption, and changes in particle size or surface properties during biological exposure. Organ distribution and target-cell association should be compared with the unmodified LNP to establish whether POx modification changes the delivery profile.

Local delivery: Local administration may be investigated when the target tissue is accessible and prolonged systemic circulation is not essential. The hydrophilic POx layer should be evaluated for its effects on particle diffusion, local retention, and cellular uptake. The route should be selected based on experimental evidence rather than assumed advantages of polymer hydrophilicity.

Nucleic acid delivery: For mRNA and siRNA formulations, the coating should preserve the ability of the ionizable lipid to interact with intracellular membranes after endocytosis. Excessive POx surface coverage may limit membrane contact and reduce productive endosomal escape. A suitable polymer length should therefore balance extracellular shielding with intracellular release.

Formulation-specific optimization: The POx-lipid fraction, polymer chain length, lipid-anchor structure, and ionizable lipid should be screened together. The optimal formulation may differ between mRNA and siRNA because payload properties and intracellular functional requirements are not identical. LNP process optimization can help assess the combined effects of lipid ratios, mixing conditions, and surface-polymer incorporation.

Delivery Verification of Poly(2-oxazoline)-Coated LNPs

In vivo delivery verification of POx-LNPs should be treated as a separate development requirement because successful polymer synthesis and in vitro transfection do not establish favorable tissue distribution or functional delivery after administration. The evaluation should include particle tracking, tissue accumulation, cellular uptake, and payload-specific activity.

Particle distribution: A traceable lipid component can be used to monitor nanoparticle-associated signals after administration. Whole-body imaging can provide an overview of distribution, while quantitative organ analysis can establish the relative accumulation in target and non-target tissues. Particle-associated signals should be interpreted together with the stability of the POx surface layer.

Target-cell uptake: Flow cytometry and microscopy can identify the cell populations associated with the formulation. Where possible, tissue analysis should distinguish surface binding from intracellular uptake. This is important because a hydrophilic polymer may improve circulation or reduce protein adsorption without increasing internalization by the intended cell population.

Intracellular delivery: Endosomal and lysosomal colocalization analysis can help identify intracellular retention. For mRNA-LNPs, reporter expression and encoded-protein quantification provide functional readouts. For siRNA-LNPs, target-gene silencing should be assessed at both transcript and protein levels when appropriate.

Repeat-dose and stability assessment: If repeated administration is part of the research plan, compare the distribution and payload activity across dosing cycles. Monitor polymer retention, particle integrity, and relevant biological responses. These studies can determine whether the selected POx architecture maintains consistent delivery behavior over time.

Because direct in vivo evidence for PEtOx-coated LNPs remains more limited than for some other PEG-free coating systems, the route and dose should be established through formulation-specific studies. BOC Sciences can support targeted LNP development and delivery evaluation to investigate the relationship between surface polymer design and tissue-level performance.

Table 4. Development and Evaluation Workflow for Poly(2-oxazoline)-Coated LNPs.

Development StageRepresentative Methods and Readouts
Synthesis MethodsCationic ring-opening polymerization, POx end-group functionalization, lipid-anchor conjugation, and microfluidic LNP formulation. Evaluate polymerization degree, molecular-weight distribution, conjugate purity, and surface incorporation.
In Vitro EvaluationDLS, PDI, cryo-TEM, zeta potential, polymer quantification, protein adsorption, encapsulation efficiency, RNA integrity, cellular uptake, intracellular localization, and reporter expression or gene silencing.
Delivery RouteIntravenous or local administration according to target accessibility, particle stability, and payload requirements. Evaluate route-dependent tissue exposure and cellular delivery.
In Vivo VerificationWhole-body imaging, organ distribution, tissue microscopy, cell-specific uptake, reporter expression, target-gene analysis, and repeat-administration evaluation where appropriate.
Exploring Poly(2-oxazoline) as a PEG-Lipid Alternative?

BOC Sciences supports POx polymer selection, molecular-weight optimization, lipid conjugation, custom synthesis, and PEG-free LNP formulation to help investigate the performance of poly(2-oxazoline)-based surface coatings.

Polysaccharide-Coated Lipid Nanoparticles

What Are Polysaccharide-Coated LNPs and When Are They Needed?

Polysaccharide-coated LNPs are nanoparticles modified with hydrophilic carbohydrate polymers that form an external surface layer. Depending on the polysaccharide structure, the coating may be neutral, negatively charged, or capable of interacting with specific biological components. Representative materials include heparosan, hyaluronic acid (HA), and selected dextran derivatives. Their molecular weight, charge density, functional groups, and attachment chemistry determine the properties of the resulting nanoparticle interface.

Heparosan is a particularly relevant material for PEG-free LNP research. It is an unsulfated glycosaminoglycan composed of repeating N-acetylglucosamine and glucuronic acid units. Its hydrophilic structure can generate a hydrated surface layer and influence interactions with serum proteins and cells. HA is another anionic polysaccharide that can be displayed on LNP surfaces through lipid anchoring, covalent conjugation, or electrostatic association. However, the biological properties of individual polysaccharides should not be assumed to be interchangeable.

Recent research has directly investigated heparosan-coated mRNA-LNPs. In this approach, a reactive lipid was included in the LNP formulation, allowing a functionalized heparosan polymer to attach to the particle surface after nanoparticle formation. The resulting formulations were characterized for particle size, PDI, surface charge, and payload encapsulation and were evaluated in cellular and mouse studies. Additional research has reported altered intracellular trafficking and sustained expression following repeated administration of selected heparosan-coated LNP formulations.

Polysaccharide coatings are particularly useful to investigate when the development objective involves a hydrated biological surface, reduced nonspecific protein interactions, or modification of cellular recognition and uptake. They can also provide functional groups for further conjugation. However, polysaccharide molecular weight, polymer charge, and attachment stability must be considered because excessive coating may increase particle size, promote interparticle interactions, or restrict access to the lipid core.

Synthesis Methods of Polysaccharide-Coated LNPs

Polysaccharide-coated LNPs can be prepared through several approaches, including covalent surface attachment, lipid-polysaccharide conjugate incorporation, and electrostatic adsorption. The appropriate method depends on the functional groups available on the polysaccharide, the surface chemistry of the LNP, and the stability required under biological conditions.

Step 1: Polysaccharide selection and functionalization. The polysaccharide should be selected according to molecular weight, charge, solubility, and intended biological interactions. Heparosan and HA contain carboxyl groups that can be used for selected conjugation strategies, while other polysaccharides may require the introduction of amino, thiol, aldehyde, or other reactive groups. Functionalization should be controlled to avoid excessive modification of the carbohydrate backbone.

Step 2: Preparation of reactive LNPs. The LNP core can be prepared with a lipid component containing an accessible reactive group. For example, a thiol-functionalized lipid can be incorporated into the lipid mixture during nanoparticle formation. Alternatively, an amino-functionalized lipid or another suitable reactive lipid can be used depending on the selected coupling chemistry. The initial particle size, PDI, surface charge, and encapsulation efficiency should be measured before surface modification.

Step 3: Polysaccharide surface attachment. One representative approach uses an orthopyridyl disulfide-functionalized heparosan polymer and a thiol-containing lipid incorporated into the LNP. Thiol-disulfide exchange enables attachment of the polysaccharide to the preformed nanoparticle surface. This strategy allows the external coating to be introduced after particle formation without requiring major changes to the original lipid-core composition.

Other polysaccharides may be attached through amide coupling, click chemistry, or electrostatic adsorption. For HA-based systems, a pre-synthesized HA-lipid conjugate can be incorporated into the lipid mixture or inserted into preformed LNPs. The selected method should be compatible with the polymer structure and the sensitivity of the encapsulated payload.

Step 4: Coating-density optimization. The polysaccharide-to-lipid ratio, polymer molecular weight, reaction conditions, and mixing sequence should be optimized. Excessive surface modification can cause steric shielding or aggregation, while insufficient coverage may result in incomplete surface functionalization. The final formulation should be evaluated for particle integrity, polymer retention, and functional payload delivery.

Purification and Characterization of Polysaccharide-Coated LNPs

Purification is important because free polysaccharide can contribute to apparent surface-charge changes or biological interactions without being attached to the LNP. The selected method must therefore distinguish particle-associated polymer from unbound material while maintaining nanoparticle recovery. Dialysis, ultrafiltration, tangential flow filtration, and size-exclusion chromatography can be evaluated according to the molecular weight of the polysaccharide and the size of the nanoparticle population.

Polymer functionalization: NMR, FTIR, and suitable electrophoretic or chromatographic techniques can be used to characterize the polysaccharide before and after functionalization. For thiol-reactive heparosan, polymer electrophoresis and an appropriate thiol-reactivity measurement can help confirm introduction of the reactive terminal group. The polymer should also be evaluated for changes in molecular-weight distribution and backbone integrity.

Surface attachment and polymer quantification: Particle-associated polysaccharide should be quantified separately from free polymer. A polymer-specific analytical method, labeled-polymer approach, or cleavage-based analysis may be used according to the attachment chemistry. For disulfide-linked systems, controlled reduction can help release surface-associated polymer for subsequent quantification. This also provides information about linker stability and possible polymer detachment.

Particle size, PDI, and zeta potential: DLS can determine hydrodynamic diameter and size distribution, while zeta potential can reveal changes associated with the polysaccharide layer. Anionic polysaccharides may shift the measured surface potential toward more negative values. However, this change should be interpreted together with direct polymer quantification because free polysaccharide can influence the measurement.

Morphology and payload integrity: Cryo-TEM can be used to examine particle morphology, while encapsulation-efficiency measurements and RNA integrity analysis determine whether the coating process has affected the payload. The coating should also be assessed for stability after exposure to physiological buffers and serum-containing media. Nanoparticle morphology characterization can complement particle-sizing and surface-charge measurements.

Colloidal and biological stability: Changes in size, PDI, zeta potential, and free-polymer concentration should be monitored during storage and biological exposure. For polysaccharides attached through cleavable linkages, the rate of polymer release should be investigated under relevant redox or enzymatic conditions. These data help distinguish a stable surface coating from a dynamic coating that is intentionally designed to detach after cellular uptake.

Delivery Strategies of Polysaccharide-Coated LNPs

Polysaccharide coatings can influence LNP delivery through changes in surface hydration, charge, protein adsorption, and interactions with extracellular components. However, the biological behavior depends on the individual carbohydrate structure. Heparosan, HA, and dextran derivatives have different molecular characteristics and should be evaluated separately rather than treated as a single interchangeable coating class.

Systemic administration: Intravenous delivery may be investigated when the target tissue is accessible through circulation. The polysaccharide layer should remain associated with the particle after serum exposure and dilution. Protein adsorption, particle size, surface charge, and organ distribution should be assessed to determine whether the coating changes circulation behavior or promotes accumulation in non-target tissues.

Intramuscular and subcutaneous administration: Local administration may be suitable when the target is accessible and local exposure is preferred. Heparosan-coated mRNA-LNPs have been investigated in mouse models following subcutaneous administration, including repeated-dose studies. These findings provide direct evidence for further research on this formulation class, but the results should not be extrapolated to all polysaccharides or administration routes.

Local tissue and receptor-associated delivery: Some polysaccharides can interact with extracellular matrix components or cellular receptors. HA, for example, can be investigated for CD44-associated cellular recognition. In such applications, the molecular weight and surface density should be optimized to maintain ligand accessibility. A hydrated carbohydrate layer should not be assumed to provide receptor-specific targeting without appropriate biological evidence.

Payload-dependent delivery: Nucleic acid LNPs require extracellular protection, cellular uptake, and cytosolic payload release. The polysaccharide layer should therefore be optimized without interfering with the ionizable lipid and helper phospholipid functions. For mRNA, functional protein expression should be measured; for siRNA, gene-silencing activity should be evaluated in the intended cell populations.

The surface modification strategy may also be combined with other formulation changes, including ionizable lipid selection, helper lipid optimization, and adjustment of the lipid-to-payload ratio. LNP encapsulation efficiency optimization can help investigate whether the polysaccharide modification changes payload retention or particle assembly.

Delivery Verification of Polysaccharide-Coated LNPs

In vivo evaluation should determine whether the polysaccharide remains associated with the LNP, changes its tissue distribution, and supports functional payload delivery. This is particularly important for coatings attached through reversible or environmentally responsive linkages. A polysaccharide signal detected in tissue may represent free polymer rather than intact polysaccharide-coated nanoparticles, so the coating, lipid component, and payload should be distinguished whenever possible.

Coating retention: The amount of particle-associated polysaccharide can be monitored before and after biological exposure. For disulfide-linked coatings, the influence of the surrounding redox environment on polymer retention should be investigated. Measurements of free and particle-associated polymer can help determine whether the surface modification remains intact during circulation and tissue distribution.

Organ-level biodistribution: Whole-body imaging and quantitative tissue analysis can determine whether polysaccharide modification changes the distribution of the LNP. The target tissue and major clearance organs should be evaluated at multiple time points. Target-to-off-target distribution is more informative than total fluorescence alone.

Cell-specific uptake: Flow cytometry and tissue microscopy can identify which cell populations associate with the coated particles. For receptor-interacting polysaccharides, receptor expression and appropriate competition or blocking controls can help determine the contribution of specific biological interactions.

Functional payload delivery: Reporter expression, encoded-protein quantification, or target-gene silencing should be used to determine whether the encapsulated payload reaches its functional destination. Intracellular trafficking measurements can further reveal whether polysaccharide modification changes endosomal retention or cytosolic delivery. Nanoparticle cellular uptake testing can complement these investigations.

Repeated administration: For formulations intended for repeat-dose research, compare tissue distribution, payload expression, and relevant immune-response indicators after successive administrations. Heparosan-coated LNP studies provide an example of repeated subcutaneous administration and sustained expression in mice. Nevertheless, the response to repeated administration should be established independently for each polymer structure and LNP composition.

Table 5. Development and Evaluation Workflow for Polysaccharide-Coated LNPs.

Development StageRepresentative Methods and Readouts
Synthesis MethodsPolysaccharide functionalization, reactive lipid incorporation, disulfide exchange or other covalent coupling, lipid-polysaccharide conjugation, and electrostatic coating. Evaluate polymer molecular weight, functional-group conversion, surface coverage, and attachment stability.
In Vitro EvaluationDLS, PDI, zeta potential, cryo-TEM, polymer quantification, free-polymer analysis, serum stability, encapsulation efficiency, RNA integrity, cellular uptake, and functional payload assays.
Delivery RouteIntravenous, intramuscular, subcutaneous, or local administration according to polysaccharide structure, target tissue, coating stability, and payload requirements.
In Vivo VerificationWhole-body imaging, organ distribution, coating-retention analysis, tissue flow cytometry, microscopy, reporter expression, gene-silencing analysis, and repeated-dose evaluation when relevant.
Developing Polysaccharide-Coated LNPs for Your Payload?

BOC Sciences provides polysaccharide selection, polymer functionalization, lipid conjugation, LNP surface modification, purification, and delivery evaluation to support the development of customized PEG-free nanoparticle coatings.

Common Failure Causes and Optimization Strategies for PEG-Free LNP Coating Development

Incomplete Surface Coverage and Residual PEG Contamination

Incomplete surface coverage can occur when the polymer-lipid conjugate has insufficient incorporation efficiency, an unsuitable lipid anchor, or poor compatibility with the underlying LNP composition. If the polymer concentration is too low, portions of the nanoparticle surface may remain exposed. This can result in heterogeneous surface properties, inconsistent protein adsorption, and variable particle stability. In post-assembly conjugation, insufficient reactive-group availability or incomplete coupling may produce similar problems.

Residual PEG contamination is a separate concern when a formulation is intended to be strictly PEG-free. PEG-containing lipid stocks, shared preparation equipment, intermediate formulations, or incompletely removed components from a previous formulation can introduce unintended PEG into the final product. A formulation that replaces most of its PEG-lipid but retains a measurable PEG-containing component should not automatically be described as completely PEG-free.

Optimization directions: Establish a controlled material inventory and verify the composition of each lipid and polymer building block. Use dedicated or appropriately cleaned preparation materials when necessary. Quantify polymer incorporation by comparing particle-associated and unbound fractions, and evaluate surface coverage using complementary chemical and physicochemical methods. For strict PEG-free development, include an appropriate analytical check for PEG-containing components rather than relying only on the nominal formulation recipe.

Polymer Molecular Weight and Grafting Density Mismatch Compromising Stability and Uptake

Polymer molecular weight and grafting density strongly influence the thickness and hydration of the external surface layer. Short polymer chains or insufficient surface density may provide inadequate steric or hydration-based protection, allowing particle aggregation and increased protein adsorption. In contrast, excessively long chains or dense polymer coverage may create a thick surface barrier that restricts membrane contact, receptor accessibility, and cellular internalization.

These effects have been observed across different PEG-free coating systems. Research involving pSar-lipids has shown that increasing polymer-chain length can reduce mRNA delivery efficiency in selected formulations. Studies involving pH-responsive polycarboxybetaine have also demonstrated that polymer length affects cellular uptake, membrane fusion, and gene-silencing activity. These findings indicate that the optimal polymer architecture is determined by the complete nanoparticle system rather than molecular weight alone.

Optimization directions: Screen multiple polymer molecular weights and surface molar fractions while keeping the underlying LNP composition controlled. Compare polymer-anchor structures, hydrodynamic diameter, PDI, surface potential, protein adsorption, and cellular uptake. Determine whether a loss of delivery activity results from excessive steric shielding or from insufficient surface protection. The final selection should balance colloidal stability and biological performance rather than maximize polymer coverage.

Coating-Induced Aggregation, Cargo Leakage, and Loss of Endosomal Escape

Surface modification can disturb the internal lipid organization or alter interactions between the nanoparticle and its surrounding aqueous environment. For example, electrostatic interactions between a charged polymer and an oppositely charged particle surface may cause charge neutralization, polymer bridging, or aggregation. Covalent conjugation may expose the payload to unfavorable pH conditions or reactive components, while excessive polymer-lipid incorporation can change lipid packing and particle self-assembly.

These changes may produce larger particles, increased PDI, reduced encapsulation efficiency, payload leakage, or decreased functional delivery. An important distinction is that high cellular uptake does not necessarily mean successful intracellular release. A thick hydrophilic surface layer can improve extracellular stability but interfere with interactions between the LNP and endosomal membranes, resulting in endosomal retention and reduced payload activity.

Optimization directions: Characterize the LNP before and after every modification step. Optimize polymer concentration, lipid-anchor fraction, reaction time, mixing conditions, pH, and buffer composition. Monitor particle size and PDI to identify aggregation and quantify encapsulation efficiency and payload integrity after purification. If cellular uptake remains high but functional delivery decreases, investigate intracellular localization and membrane interaction rather than simply increasing the polymer concentration.

The ionizable lipid and helper phospholipid should also be reconsidered when endosomal escape is reduced. Surface coating and core lipid composition are interdependent, so adjustments to one component may require re-optimization of the others. LNP endosomal escape evaluation can help identify whether poor delivery results from intracellular trapping or insufficient cytosolic payload release.

Rapid Clearance and Off-Target Biodistribution After Repeat Dosing

Replacing PEG does not guarantee prolonged circulation or consistent delivery after repeated administration. PEG-free polymers can still interact with serum proteins, complement components, and immune cells. In addition, the underlying ionizable lipid, particle size, surface charge, and administration route can influence organ distribution and clearance. A coating that performs well after a single administration may behave differently following repeated exposure.

Off-target biodistribution can also occur when the polymer layer changes the biological identity of the nanoparticle. Altered protein adsorption may increase association with certain cell populations or promote uptake by clearance organs. Similarly, a formulation may reach the intended organ but fail to deliver the payload to the relevant cell type or intracellular compartment. These outcomes should be distinguished from simple nanoparticle accumulation.

Optimization directions: Compare single-dose and repeat-dose performance using consistent particle composition and administration conditions. Evaluate whole-body distribution, organ accumulation, target-cell uptake, and functional payload activity at multiple time points. Monitor relevant immune-response indicators and investigate whether the polymer coating remains associated with the LNP after administration. If clearance or off-target accumulation increases, reassess polymer molecular weight, surface density, lipid-anchor retention, and the underlying ionizable lipid composition.

A useful optimization workflow should compare unmodified LNPs and different PEG-free coating architectures while keeping the payload and core formulation controlled. This allows the contribution of surface chemistry to be distinguished from the effects of the underlying lipid composition. LNP transfection troubleshooting services can support the investigation of poor cellular uptake, intracellular trafficking, and reduced functional delivery.

Facing Challenges in PEG-Free LNP Coating Development?

BOC Sciences has experienced technical specialists who can help investigate incomplete surface coverage, polymer-lipid conjugation problems, particle aggregation, payload leakage, reduced endosomal escape, and unfavorable in vivo distribution through systematic formulation analysis and optimization.

BOC Sciences Support for PEG-Free LNP Coating Development

Polymer-Lipid Building Block Selection and Custom Synthesis

The selection of polymer and lipid building blocks determines the molecular architecture and surface properties of PEG-free LNPs. BOC Sciences can support the selection of zwitterionic polymers, polysarcosine, poly(2-oxazoline), and polysaccharides according to the intended surface characteristics and payload requirements. Important selection parameters include polymer molecular weight, degree of polymerization, charge characteristics, terminal functional groups, hydrophilicity, and lipid-anchor structure.

Custom synthesis may be considered when commercially available materials do not provide the required molecular weight, functional-group availability, or conjugation architecture. For example, pSar-lipid development may require control over polymer length and hydrophobic anchor composition, while POx-lipid synthesis may require defined polymer end groups for subsequent coupling. Zwitterionic and polysaccharide materials may require additional functionalization to support covalent attachment or controlled surface assembly.

BOC Sciences can support project-specific material preparation through polymer synthesis, lipid-anchor selection, polymer-lipid conjugation, and chemical characterization. The objective is to provide building blocks with suitable molecular properties for subsequent LNP formulation and surface modification.

Surface Coating and LNP Functionalization Services

Different PEG-free polymers require different surface-modification strategies. BOC Sciences can support the selection and development of pre-insertion, post-insertion, post-assembly covalent conjugation, and electrostatic coating approaches according to the chemistry of the polymer and the existing LNP formulation.

For polymer-lipid conjugate systems, the development process can focus on conjugate incorporation, lipid-anchor retention, polymer surface density, and coating uniformity. For reactive surface attachment, the availability of functional groups on the nanoparticle and the compatibility of coupling conditions with the payload should be considered. For polysaccharide-based coatings, charge interactions and polymer retention require particular attention.

BOC Sciences provides nanoparticle surface functionalization services and nanoparticle conjugation services to support the development of customized surface architectures. The appropriate approach is selected according to the desired surface properties, reactive groups, and compatibility with the original LNP core.

LNP Formulation, Purification, and Physicochemical Characterization

Successful PEG-free LNP development requires coordinated optimization of the surface polymer and the underlying lipid composition. BOC Sciences can support the selection of ionizable lipids, helper phospholipids, cholesterol, polymer-lipid conjugates, and other formulation components. The formulation process can be adjusted according to payload type, particle size requirements, and the intended administration route.

Microfluidic mixing and other suitable nanoparticle preparation methods can be evaluated to establish reproducible particle formation. Purification development may include dialysis, ultrafiltration, tangential flow filtration, or size-based separation according to the formulation and free-component profile. The objective is to remove unincorporated polymers, residual reaction components, and organic solvents while maintaining high nanoparticle recovery and payload integrity.

Physicochemical characterization can include particle size, PDI, zeta potential, morphology, polymer incorporation, encapsulation efficiency, payload integrity, and colloidal stability. These measurements should be interpreted together to determine whether the coating has been successfully introduced without compromising the nanoparticle core. BOC Sciences can also support LNP excipient screening to compare alternative surface materials and formulation components.

In Vitro and In Vivo Delivery Evaluation Services

The biological performance of a PEG-free coating cannot be established through physicochemical characterization alone. BOC Sciences can support cellular uptake, intracellular localization, endosomal escape, and functional payload delivery studies to determine whether surface modification improves the intended biological outcome. These evaluations can be designed around the specific payload, target-cell population, and delivery mechanism.

For mRNA-containing LNPs, reporter expression and encoded-protein measurements can help assess functional delivery. For siRNA formulations, target-gene and protein reduction can provide complementary readouts. Cellular uptake should be evaluated together with intracellular trafficking to distinguish particle internalization from productive cytosolic delivery. BOC Sciences also provides nanoparticle in vitro evaluation to support these investigations.

In vivo evaluation can include whole-body imaging, organ distribution, tissue-level particle accumulation, cell-specific uptake, and payload activity. The assessment can be extended to repeated administration when relevant to the research objective. The resulting data can guide further optimization of polymer molecular weight, lipid-anchor composition, surface density, and administration route.

BOC Sciences can integrate these results into a coordinated development workflow, helping researchers determine whether a selected PEG-free coating provides an appropriate balance between nanoparticle stability, biological interactions, cellular uptake, and functional payload delivery.

Table 6. BOC Sciences Services for PEG-Free LNP Coating Development.

Service NameDescriptionInquiry
PEG-Free Polymer-Lipid Building Block Custom SynthesisCustom preparation of zwitterionic, polysarcosine, poly(2-oxazoline), and polysaccharide-based materials with selected molecular weights, terminal groups, and lipid-anchor structures.Inquiry
PEG-Free LNP Surface FunctionalizationDevelopment of polymer-lipid incorporation, post-assembly conjugation, and noncovalent coating strategies with optimization of surface coverage and polymer retention.Inquiry
Custom PEG-Free LNP FormulationSelection of lipid components, polymer-lipid ratios, payload encapsulation, and formulation optimization for customized PEG-free nanoparticle systems.Inquiry
PEG-Free LNP Purification and CharacterizationEvaluation of particle size, PDI, zeta potential, morphology, polymer incorporation, payload encapsulation, RNA integrity, and colloidal stability.Inquiry
PEG-Free LNP Cellular Uptake and Intracellular Delivery EvaluationAssessment of cellular association, internalization, intracellular localization, endosomal escape, reporter expression, and gene-silencing activity.Inquiry
PEG-Free LNP In Vivo Biodistribution and Delivery EvaluationWhole-body imaging, organ distribution, tissue-level nanoparticle analysis, cell-specific uptake, and functional payload delivery assessment.Inquiry

Conclusion

PEG-free lipid nanoparticle coatings provide several approaches for modifying the nanoparticle-biointerface without relying on conventional PEG-lipids. Zwitterionic polymers offer strongly hydrated surfaces with tunable charge characteristics, polysarcosine provides a neutral hydrophilic polymer layer, poly(2-oxazoline) offers adjustable synthetic polymer architectures, and polysaccharides provide biologically derived surface structures with distinct charge and interaction properties. Each coating type has different requirements for polymer synthesis, lipid conjugation, surface incorporation, purification, and biological evaluation. Successful development therefore depends on optimizing polymer molecular weight, lipid-anchor structure, surface density, coating stability, and compatibility with the encapsulated payload. Importantly, improved colloidal stability or cellular uptake does not necessarily demonstrate successful in vivo delivery. Integrated physicochemical characterization, cellular uptake analysis, intracellular trafficking, biodistribution, and functional payload measurements are required to establish the performance of the final formulation. BOC Sciences provides polymer-lipid building block selection, custom synthesis, LNP surface functionalization, formulation optimization, purification, characterization, and cellular and in vivo delivery evaluation to support the development of customized PEG-free lipid nanoparticle platforms.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code